The immunological and genetic basis of inflammatory bowel disease

Nature Reviews Immunology

Volumn 3, Issue 7, 2003, Pages 521-533

  Bouma, Gerd ^a,b   Strober, Warren ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; ACETIC ACID; AZATHIOPRINE; CARRAGEENAN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; CYCLOSPORIN; GAMMA INTERFERON; INDOMETACIN; INTERLEUKIN 12; INTERLEUKIN 13; MERCAPTOPURINE; METHOTREXATE; OXAZOLONE; PEPTIDOGLYCAN POLYSACCHARIDE; PROTEIN; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

COLON RESECTION; CROHN DISEASE; CYTOKINE PRODUCTION; ENTERITIS; EPIDEMIOLOGICAL DATA; GENE IDENTIFICATION; GENE MUTATION; GENETIC DISORDER; HEREDITY; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; IMMUNOREGULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ANIMALS; CARRIER PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; INFLAMMATORY BOWEL DISEASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; TH1 CELLS; TH2 CELLS;

EID: 0142053206     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1132     Document Type: Review

References (138)

1. Podolsky, D. K. Inflammatory bowel disease. N. Engl. J. Med. 347, 417-429 (2002).
2. Blumberg, R. S., Saubermann, L. J. & Strober, W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr. Opin. Immunol. 11, 648-656 (1999).
3. Strober, W., Fuss, I. J. & Blumberg, R. S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20, 495-549 (2002).
4. Mahler, M. & Leiter, E. H. Genetic and environmental context determines the course of colitis developing in IL-10 deficient mice. Inflammatory Bowel Diseases 8, 347-355 (2002).
5. Sartor, R. B. The influence of normal bacterial flora in the development of chronic mucosal inflammation. Res. Immunol. 148, 467-476 (1997).
6. + T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J. Exp. Med. 187, 855-864 (1998). This study shows that T cells that are reactive with conventional antigens of the enteric bacterial flora can mediate chronic inflammatory bowel disease (IBD).
7. Sartor, R. B. in Inflammatory Bowel Diseases (ed. Kirshner, J. B.) 153-178 (Saunders, Philadelphia/London, 1999).
8. Madsen, K. L., Doyle, J. S. Jewell, L. D., Tavernini, M. M. & Fedorak, R. N. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116, 1107-14 (1999).
9. Karlsson, M. R., Kahu, H., Hanson, L. A., Telemo, E. & Dahlgren, U. I. Neonatal colonization of rats induces immunological tolerance to bacterial antigens. Eur. J. Immunol. 29, 109-118 (1999).
10. Kontoyiannis, D., Pasparakis, M., Pizarro, T. T., Cominelli, F. & Kollias, G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10, 387-398 (1999).
11. + T cells that respond to bacterial antigens. J. Immunol. 162, 1884-1888 (1999).
12. Bouma, G., Kaushiva, A. & Strober, W. Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses. Gastroenterol. 123, 554-565 (2002). This study shows that the intrinsic ability to mount a high interleukin-12 (IL-12) response to constituents of the enteric flora is genetically linked to colitis susceptibility.
13. Strober, W., Kelsall, B. & Marth, T. Oral tolerance. J. Clin. Immunol. 18, 1-30 (1998).
14. H1)-cell responses, and that colitis can occur as the consequence of deficient or absent T-cell regulatory function.
15. + T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. 179, 589-600 (1994).
16. Kuhn, R., Lohler, J., Rennick, D., Rajewsky, K. & Muller, W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75, 263-274 (1993). This study was published together with references 117 and 124 in the same issue of Cell, and showed that inactivation of entirely different immune genes can lead to spontaneous intestinal inflammation, providing strong evidence for the presence of genetic heterogeneity in IBD.
17. Gorelik, L. & Flavell, R. A. Abrogation of TGF-β signalling in T cells leads to spontaneous T cell differentiation of autoimmune disease. Immunity 12, 171-181 (2000).
18. Hollander, G. A. et al. Severe colitis in mice with aberrant thymic selection. Immunity 3, 27-38 (1995). This study showed that T cells selected in an aberrant thymic microenvironment contain a population of cells that can induce severe colitis that can be prevented by T cells that have undergone normal thymic development, and so emphasizes the role of the thymus in the development of T regulatory cells.
19. + regulatory T cells. J. Immunol. 170, 3939-3943 (2003).
20. Neurath, M. F., Fuss, I., Kelsall, B. L., Stuber, E. & Strober, W. Antibodies to interleukin-12 abrogate established experimental colitis in mice. J. Exp. Med. 182, 1281-1290 (1995). This study describes the importance of IL-12 in chronic granulomatous colitis, and the effectiveness of antibodies specific for IL-12 in these diseases.
21. Boinvant, M., Fuss, I. J., Chu, A. & Strober, W. Oxazalone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188, 129-139 (1998).
22. H2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17, 629-638 (2002). This study shows that production of IL-13 is a important pathological factor in a mouse model for ulcerative colitis, and shows that such colitis is mediated by natural killer T (NKT) cells.
23. Carlo, E. et al. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J. Immunol. 164, 966-972 (2000).
24. Gewirtz, A. T., Navas, T. A., Lyons, S., Godowski, P. J. & Madara, J. L. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J. Immunol. 167, 1882-1885 (2001).
25. Maaser, C. & Kagnoff, M. F. Role of the intestinal epithelium in orchestrating innate and adaptive mucosal immunity. Gastroenterol. 40, 525-529 (2002).
26. Cario, E. & Podolsky, D. K. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 68, 7010-7017 (2000).
27. Podolsky, D. K. Mucosal immunity and inflammation. V. Innate mechanisms of mucosal defense and repair: the best offense is a good defense. Am. J. Physiol. 277, G495-G499 (1999).
28. Hermiston, M. L. & Gordon, J. I. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 270, 1203-1207 (1995). The possibility that defects that change the physical relationship between the mucosal immune system and the microflora can lead to mucosal inflammation was shown in this paper.
29. H1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39-49 (1999).
30. Monteleone, G. et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterol. 112, 1169-1178 (1997).
31. Parronchi, P. et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. J. Pathol. 150, 823-832 (1997).
32. Liu, Z. et al. Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production. J. Immunol. 163, 4049-4057 (1999).
33. Parrello, T. et al. Upregulation of the IL-12 receptor β2 chain in Crohn's disease. J. Immunol. 165, 7234-7239 (2000).
34. Neurath, M. F. et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 159, 1129-1133 (2002).
35. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157, 1261-1270 (1996). This study provides strong evidence that the immunopathological process that is characteristic of the two main forms of IBD - Crohn's disease and ulcerative colitis - is associated with different cytokine-secretion patterns.
36. Oppmann, B. et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13, 715-725 (2000).
37. Cua, D. J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748 (2003).
38. Saxon, A., Shanahan, F., Landers, C., Ganz, T. & Targan, S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease J. Allergy Clin. Immunol. 86, 202-210 (1990).
39. Das, K. M., Dasgupta, A., Mandal, A. & Geng, X. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanism for ulcerative colitis. J. Immunol. 150, 2487-2493 (1993).
40. Kett, K., Rognum, T. O. & Brandtzaeg, P. Mucosal subclass distribution of immunoglobulin G-producing cells is different in ulcerative colitis and Crohn's disease of the colon. Gastroenterol. 93, 919-924 (1987).
41. Christ, A. D. et al. An interleukin 12-related cytokine is upregulated in ulcerative colitis but not in Crohn's disease. Gastroenterol. 115, 307-313 (1998).
42. Liu, Z. et al. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J. Immunol. 164, 3608-3615 (2000).
43. Seegert, D. et al. Increased expression of IL-16 in inflammatory bowel disease. Gut 48, 326-332 (2001).
44. Pages, F. et al. Analysis of interleukin-18, interleukin-1 converting enzyme (ICE) and interleukin-18-related cytokines in Crohn's disease lesions. Eur. Cytokine Netw. 12, 97-104 (2001).
45. Breese, E. J. et al. Tumor necrosis factor α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterol. 106, 1455-1466 (1994).
46. Reinecker, H. C. et al. Enhanced secretion of tumour necrosis factor-α, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 94, 174-181 (1993).
47. Chen, Y., Kuchroo, V. K., Inobe, J., Hafler, D. A. & Weiner, H. L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265, 1237-1240 (1994).
48. H2 and more. Immunol. Today 17, 138-146 (1996).
49. Duchmann, R. et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin. Exp. Immunol. 102, 448-455 (1995).
50. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995).
51. Sakaguchi, S. et al. T cell-mediated maintenance of natural self-tolerance: its breakdown as a possible cause of various autoimmune diseases. J. Autoimmun. 9, 211-220 (1996).
52. + regulatory T cells through GITR breaks immunological self-tolerance. Nature Immunol. 3, 135-142 (2002).
53. + regulatory T cells induced by an agonist self-peptide. Nature Immunol. 2, 301-306 (2001).
54. Hori, S., Nomura, T. & Sakaguchi, N. Control of regulatory T cell development by the transcription factor FoxP3. Science 299, 1057-1061 (2003).
55. Wildin, R. S., Smyk-Pearson, S. & Filipovich, A. H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J. Med. Genet. 39, 537-545 (2002).
56. + immunoregulatory T cells is antigen nonspecific. J. Immunol. 164, 183-190 (2000).
57. + T cells exert immunosuppression by a cell-cell interaction that involves cell surface transforming-growth factor-β (TGF-β)
58. + human thymocytes. J. Exp. Med. 196, 379-387 (2002).
59. + T cells. J. Exp. Med. 183, 2669-2674 (1996).
60. + regulatory T cells can mediate suppressor function in the absence of transforming growth factor-β1 production and responsiveness. J. Exp. Med. 196, 237-246 (2002).
61. + regulatory T cells by oral antigen administration. J. Immunol. 167, 425-435 (2001).
62. + T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen. J. Immunol. 167, 188-195 (2001).
63. Monteleone, G. et al. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108, 601-609 (2001).
64. + T-cell subset that develops under the influence of IL-10, which can suppress antigen-specific immune responses.
65. Levings, M. K., Bacchetta, R., Schulz, U. & Roncarolo, M. G. The role of IL-10 and TGF-β in the differentiation and effector function of T regulatory cells. Int. Arch. Allergy Immunol. 129, 263-276 (2002).
66. Apostolou, I., Sarukhan, A., Klein, L. & von Boehmer, H. Origin of regulatory T cells with known specificity for antigen. Nature Immunol. 3, 756-763 (2002).
67. + T suppressor cell clones produce transforming growth factor-β, but not interleukin 10, and are distinct from type 1 T regulatory cells. J. Exp. Med. 196, 1335-1346 (2002).
68. Bacchetta, R. et al. Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. Eur. J. Immunol. 32, 2237-2245 (2002).
69. McGuirk, P., McCann, C. & Mills, K. H. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exp. Med. 195, 221-231 (2002).
70. + T regulatory cells suppress Helicobacter hepaticus-induced colitis. J. Exp. Med. 196, 505-515 (2002).
71. +, and double-negative Peyer's patch dendritic cells. J. Immunol. 166, 4884-4890 (2001).
72. Akbari, O., DeKruyff, R. H. & Umetsu, D. T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nature Immunol. 2, 725-731 (2001).
73. Fuss, I. J., Boirivant, M., Lacy, B. & Strober, W. The interrelated roles of TGF-β and IL-10 in the regulation of experimental colitis. J. Immunol. 168, 900-908 (2002).
74. + T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterol. 123, 1516-1526 (2002).
75. Campbell, N. A. et al. A non-class I MHC intestinal epithelial surface glycoprotein, gp180, binds to CD8. Clin. Immunol. 102, 267-274 (2002).
76. Mayer, L. & Eisenhardt, D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J. Clin. Invest. 86, 1255-1260 (1990).
77. Toy, L. S., Yio, X. Y., Lin, A., Honig, S. & Mayer, L. Defective expression of gp180, a novel CD8 ligand on intestinal epithelial cells, in inflammatory bowel disease. J. Clin. Invest. 100, 2062-2071 (1997).
78. Bonen, K. B. & Cho, J. H. The genetics of inflammatory bowel disease. Gastroenterol. 124, 532-536 (2003).
79. Yang, H. & Rotter, J. I. in Inflammatory Bowel Disease: From Bench to Bedside (eds Targan, S. R. & Shanahan, F.) 32-64 (Milliam and Wilkins, Baltimore, 1994).
80. Tysk, C., Lindberg, E., Jarnerot, G. & Floderus-Myrhed, B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 29, 990-996 (1988).
81. Orholm, M., Binder, V., Sorensen, T. I., Rasmussen, L. P. & Kyvik, K. O. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand. J. Gastroenterol. 35, 1075-1081 (2000).
82. Thompson, N. P., Driscoll, R., Pounder, R. E. & Wakefield, A. J. Genetics versus environment in inflammatory bowel disease: results of a British twin study. BMJ 312, 95-96 (1996).
83. Hugot, J. P. et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 379, 821-823 (1996).
84. Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001). This study was published concomitantly with reference 87, describing mutations in the gene encoding NOD2 (nucleotide-binding oligomerization domain 2) protein as the cause of Crohn's disease in a subgroup of patients.
85. Girardin, S. E. et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278, 8869-8872 (2003).
86. Inohara, N. et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2: implications for Crohn's disease. J. Biol. Chem. 278, 5509-5512 (2003).
87. Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603-606 (2001).
88. Hampe, J. et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357, 1925-1928 (2001).
89. van der Linde, K. et al. CARD15 and Crohn's disease: healthy homozygous carriers of the 3020insC frameshift mutation. Am. J. Gastroenterol. 98, 613-617 (2002).
90. Yamazaki, K., Takazoe, M., Tanaka, T., Kazumori, T. & Nakamura, Y. Absence of mutation in the NOD2/CARD15 gene among 483 Japanese patients with Crohn's disease. J. Hum. Genet. 47, 469-472 (2002).
91. Inohara, N., Ogura, Y. & Nunez, G. Nods: a family of cytosolic proteins that regulate the host response to pathogens. Curr. Opin. Microbiol. 5, 76-80 (2002).
92. Inohara, N. & Nunez, G. The NOD: a signaling module that regulates apoptosis and host defense against pathogens. Oncogene 20, 6473-6481 (2001).
93. Gutierrez, O. et al. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-κB. J. Biol. Chem. 277, 41701-41705 (2002).
94. Kobayashi, K. et al. RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416, 194-199 (2002).
95. Ogura, Y. et al. Genetic variation and activity of mouse Nod2, a susceptibility gene for Crohn's disease small star, filled. Genomics 81, 369-377 (2003).
96. Rioux, J. D. et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am. J. Hum. Genet. 66, 1863-1870 (2000).
97. Kobayashi, M. et al. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J. Clin. Invest. 111, 1297-1308 (2003).
98. Mahler, M. et al. Genetic analysis of susceptibility to dextran sulfate sodium-induced colitis in mice. Genomics 55, 147-156 (1999).
99. Mahler, M. et al. Genetics of colitis susceptibility in IL-10-deficient mice: backcross versus F2 results contrasted by principal component analysis. Genomics 80, 274-282 (2002).
100. Farmer, M. A. et al. A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice. Proc. Natl Acad. Sci. USA 98, 13820-13825 (2001).
101. Kozaiwa, K. et al. Genetic analysis of susceptibility to ileitis in a spontaneous mouse model of Crohn's disease. Gastroenterol. 120, A186 (2001).
102. Targan, S. R. Biology of inflammation in Crohn's disease: mechanisms of action of anti-TNF-α therapy. Can. J. Gastroenterol. 14, C13-C16 (2000).
103. Neurath, M. F. et al. Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol. 22, 21-26 (2001).
104. H1 T cells in experimental colitis in mice. Gastroenterol. 117, 1078-1088 (1999).
105. Atreya, R. et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nature Med. 6, 583-588 (2000).
106. + T lymphocytes. J. Clin. Invest. 111, 1133-1145 (2003).
107. van Assche, G. & Rutgeerts, P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm. Bowel Dis. 8, 291-300 (2002).
108. Ghosh, S. et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348, 24-32 (2003).
109. Steidler, L. et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289, 1352-1355 (2000).
110. Kitani, A. et al. Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-β1 plasmid: TGF-β1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor-β2 chain downregulation. J. Exp. Med. 192, 41-52 (2000).
111. Madara, J. L. et al. Characterization of spontaneous colitis in cotton-top tamarins (Saguinus oedipus) and its response to sulfasalazine. Gastroenterol. 88, 13-19 (1985).
112. Matsumoto, S. et al. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 43, 71-78 (1998).
113. Rivera-Nieves, J. et al. Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterol. 124, 972-982 (2003). The model of spontaneous intestinal inflammation used in references 112 and 113 has a macroscopic and microscopic appearance that is markedly similar to that of Crohn's disease, including predominant small-bowel involvement and the development of peri-anal fistulas
114. Sundberg, J. P., Elson, C. O., Bedigian, H. & Birkenmeier, E. H. Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterol. 107, 1726-1735 (1994).
115. Panwala, C. M., Jones, J. C. & Viney, J. L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 161, 5733-5744 (1998).
116. Mashimo, H., Wu, D. C., Podolsky, D. K. & Fishman, M. C. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274, 262-265 (1996).
117. Sadlack, B. et al. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75, 253-261 (1993).
118. Willerford, D. M. et al. Interleukin-2 receptor-α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3, 521-530 (1995).
119. Spencer, S. D. et al. The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J. Exp. Med. 187, 571-578 (1998).
120. Shull, M. M. et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359, 693-699 (1992).
121. Hahm, K. B. et al. Loss of transforming growth factor-β signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 49, 190-198 (2001).
122. Rudolph, U. et al. Ulcerative colitis and adenocarcinoma of the colon in Gαi2-deficient mice. Nature Genet. 10, 143-150 (1995).
123. Watanabe, M. et al. The serum factor from patients with ulcerative colitis that induces T cell proliferation in the mouse thymus is interleukin-7. J. Clin. Immunol. 17, 282-292 (1997).
124. Mombaerts, P. et al. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 75, 274-282 (1993).
125. Erdman, S., Fox, J. G., Dangler, C. A., Feldman, D. & Horwitz, B. H. Typhlocolitis in NF-κB-deficient mice. J. Immunol. 166, 1443-1447 (2001).
126. Beg, A. A., Sha, W. C., Bronson, R. T., Ghosh, S. & Baltimore, D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 376, 167-170 (1995).
127. Lee, E. G. et al. Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science 289, 2350-2354 (2000).
128. Hammer, R. E., Maika, S. D., Richardson, J. A., Tang, J. P. & Taurog, J. D. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: an animal model of HLA-B27-associated human disorders. Cell 63, 1099-1112 (1990).
129. Snapper, S. B. et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity 9, 81-91 (1998).
130. Morris, G. P. et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterol. 96, 795-803 (1989).
131. MacPherson, B. R. & Pfeiffer, C. J. Experimental production of diffuse colitis in rats. Digestion 17, 135-150 (1978).
132. Yamada, T., Sartor, R. B., Marshall, S., Specian, R. D. & Grisham, M. B. Mucosal injury and inflammation in a model of chronic granulomatous colitis in rats. Gastroenterol. 104, 759-771 (1993).
133. Okayasu, I. et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterol. 98, 694-702 (1990).
134. Stewart, T. H., Hetenyi, C., Rowsell, H. & Orizaga, M. Ulcerative enterocolitis in dogs induced by drugs. J. Pathol. 131, 363-378 (1980).
135. Watt, J. & Marcus, R. Ulcerative colitis in the guinea-pig caused by seaweed extract. J. Pharm. Pharmacol. 21, S187 (1969).
136. Steinhoff, U. et al. Autoimmune intestinal pathology induced by hsp60-specific CD8 T cells. Immunity 11, 349-358 (1999).
137. Teuscher, C. et al. Sequence polymorphisms in the chemokines Scya1 (TCA-3), Scya2 (monocyte chemoattractant protein (MCP)-1), and Scya12 (MCP-5) are candidates for eae7, a locus controlling susceptibility to monophasic remitting/nonrelapsing experimental allergic encephalomyelitis. J. Immunol. 163, 2262-2266 (1999).
138. Morahan, G. et al. Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nature Genet. 27, 218-221 (2001).